Abstract
(Int J Obstet Anesth. 2018;36:85–95) Monitoring cardiac output (CO) in pregnant patients has been suggested as a means to improve outcomes for mother and child as blood pressure and clinical signs may not be sufficient proxys for CO. Currently, the gold standard for CO measurement is the thermodilution technique via a pulmonary artery catheter or transthoracic echocardiography (TTE). This study aimed to evaluate the Clearsight, a noninvasive hemodynamic monitoring system that uses “volume clamp” technology to produce a continuous arterial BP wave, as a valid monitor of CO and stroke volume (SV) in parturients compared with TTE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
